Role of protein tyrosine phosphatases in the modulation of insulin signaling and their implication in the pathogenesis of obesity-linked insulin resistance

Reviews in Endocrine and Metabolic Disorders

Volumn 15, Issue 1, 2014, Pages 79-97

  Xu, Elaine ^a   Schwab, Michael ^a   Marette, André ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Diabetes; Insulin signaling; Metabolism; Obesity; Protein tyrosine phosphatase

Indexed keywords

INSULIN; INSULIN RECEPTOR; LEUKOCYTE COMMON ANTIGEN RELATED PHOSPHATASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDATE PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN SH2; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; UNCLASSIFIED DRUG;

ENZYME ACTIVITY; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; HUMANS; INSULIN; INSULIN RESISTANCE; OBESITY; PROTEIN TYROSINE PHOSPHATASES; SIGNAL TRANSDUCTION;

EID: 84896305265     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-013-9282-4     Document Type: Review

References (283)

1. Waxman A. WHO global strategy on diet, physical activity and health. Food Nutr Bull. 2004;25(3):292-302. (Pubitemid 39379377)
2. O'Sullivan JB, Mahan CM. Blood sugar levels, glycosuria, and body weight related to development of diabetes mellitus. The Oxford epidemiologic study 17 years later. JAMA. 1965;194(6):587-92.
3. Wilson PW, McGee DL, Kannel WB. Obesity, very low density lipoproteins, and glucose intolerance over fourteen years: the Framingham study. Am J Epidemiol. 1981;114(5):697-704. (Pubitemid 12241742)
4. Weyer C et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86(5):1930-5. (Pubitemid 32472900)
5. McKenney RL, Short DK. Tipping the balance: the pathophysiology of obesity and type 2 diabetes mellitus. Surg Clin N Am. 2011;91(6):1139-48. vii.
6. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med. 2010;363(24):2339-50.
7. Smyth S, Heron A. Diabetes and obesity: the twin epidemics. Nat Med. 2006;12(1):75-80. (Pubitemid 43050080)
8. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173-94.
9. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148(5):852-71.
10. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav. 2008;94(2):206-18. (Pubitemid 351615418)
11. Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev. 2007;21(12):1443-55. (Pubitemid 46955717)
12. Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 2007;87(2):507-20. (Pubitemid 47084679)
13. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106(4):473-81. (Pubitemid 30666380)
14. Opie LH, Walfish PG. Plasma free fatty acid concentrations in obesity. N Engl J Med. 1963;268:757-60.
15. Bjorntorp P, Bergman H, Varnauskas E. Plasma free fatty acid turnover rate in obesity. Acta Med Scand. 1969;185(4):351-6.
16. Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes. 2011;60(10):2441-9.
17. Boden G. Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes. 2011;18(2):139-43.
18. Randle PJ et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1(7285):785-9.
19. Pan DA et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes. 1997;46(6):983-8. (Pubitemid 27220998)
20. Roden M et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest. 1996;97(12):2859-65. (Pubitemid 26197099)
21. Boden G et al. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J Physiol Endocrinol Metab. 2002;283(1):E12-9. (Pubitemid 34686662)
22. Lam TK et al. Mechanisms of the free fatty acid-induced increase in hepatic glucose production. Am J Physiol Endocrinol Metab. 2003;284(5):E863-73. (Pubitemid 36444021)
23. Wu N et al. Taurine prevents free fatty acid-induced hepatic insulin resistance in association with inhibiting JNK1 activation and improving insulin signaling in vivo. Diabetes Res Clin Pract. 2010;90(3):288-96.
24. Morita S, et al. Effect of exposure to non-esterified fatty acid on progressive deterioration of insulin secretion in patients with Type 2 diabetes: a long-term follow-up study. Diabet Med. 2012;29(8):980-5.
25. Koyama K et al. Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. Am J Physiol. 1997;273(4 Pt 1):E708-13.
26. Oprescu AI et al. Free fatty acid-induced reduction in glucose-stimulated insulin secretion: evidence for a role of oxidative stress in vitro and in vivo. Diabetes. 2007;56(12):2927-37. (Pubitemid 350223627)
27. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793-801. (Pubitemid 44033299)
28. Tremblay F et al. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci U S A. 2007;104(35):14056-61. (Pubitemid 350003334)
29. Klip A, Paquet MR. Glucose transport and glucose transporters in muscle and their metabolic regulation. Diabetes Care. 1990;13(3):228-43. (Pubitemid 20092110)
30. Heuson JC, Coune A, Heimann R. Cell proliferation induced by insulin in organ culture of rat mammary carcinoma. Exp Cell Res. 1967;45(2):351-60.
31. Wang W et al. Mediator MED23 links insulin signaling to the adipogenesis transcription cascade. Dev Cell. 2009;16(5):764-71.
32. Pause A et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature. 1994;371(6500):762-7.
33. Fulzele K et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell. 2010;142(2):309-19.
34. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799-806. (Pubitemid 34000783)
35. Buchanan KD, Mawhinney WA. Insulin control of glucagon release from insulin-deficient rat islets. Diabetes. 1973;22(11):801-3.
36. Koch L et al. Central insulin action regulates peripheral glucose and fat metabolism in mice. J Clin Invest. 2008;118(6):2132-47. (Pubitemid 351872332)
37. Konner AC et al. Role for insulin signaling in catecholaminergic neurons in control of energy homeostasis. Cell Metab. 2011;13(6):720-8.
38. Bruning JC et al. Role of brain insulin receptor in control of body weight and reproduction. Science. 2000;289(5487):2122-5.
39. Fisher SJ et al. Insulin signaling in the central nervous system is critical for the normal sympathoadrenal response to hypoglycemia. Diabetes. 2005;54(5):1447-51. (Pubitemid 40586676)
40. Hill JW et al. Direct insulin and leptin action on pro-opiomelanocortin neurons is required for normal glucose homeostasis and fertility. Cell Metab. 2010;11(4):286-97.
41. Konner AC et al. Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production. Cell Metab. 2007;5(6):438-49. (Pubitemid 46825497)
42. Lee JC, Downing SE. Effects of insulin on cardiac muscle contraction and responsiveness to norepinephrine. Am J Physiol. 1976;230(5):1360-5.
43. Maier S et al. Stimulation of L-type Ca2+ current in human atrial myocytes by insulin. Cardiovasc Res. 1999;44(2):390-7. (Pubitemid 29474100)
44. Gupta AK, Clark RV, Kirchner KA. Effects of insulin on renal sodium excretion. Hypertension. 1992;19(1 Suppl):I78-82.
45. Alvestrand A et al. Insulin-mediated potassium uptake is normal in uremic and healthy subjects. Am J Physiol. 1984;246(2 Pt 1):E174-80. (Pubitemid 14147692)
46. Breen DM, Giacca A. Effects of insulin on the vasculature. Curr Vasc Pharmacol. 2011;9(3):321-32.
47. Rubinsztein DC, Marino G, Kroemer G. Autophagy and aging. Cell. 2011;146(5):682-95.
48. Muller D et al. Identification of insulin signaling elements in human beta-cells: autocrine regulation of insulin gene expression. Diabetes. 2006;55(10):2835-42. (Pubitemid 44923684)
49. Kulkarni RN et al. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell. 1999;96(3):329-39. (Pubitemid 29077587)
50. Lim GE et al. Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. Endocrinology. 2009;150(2):580-91.
51. Kovacina KS, Roth RA. Characterization of the endogenous insulin receptor-related receptor in neuroblastomas. J Biol Chem. 1995;270(4):1881-7.
52. Butler AA, LeRoith D. Minireview: tissue-specific versus generalized gene targeting of the igf1 and igf1r genes and their roles in insulin-like growth factor physiology. Endocrinology. 2001;142(5):1685-8. (Pubitemid 32405920)
53. Patti ME, Kahn CR. The insulin receptor-a critical link in glucose homeostasis and insulin action. J Basic Clin Physiol Pharmacol. 1998;9(2-4):89-109. (Pubitemid 29143595)
54. De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov. 2002;1(10):769-83. (Pubitemid 37361561)
55. Lizcano JM, Alessi DR. The insulin signalling pathway. Curr Biol. 2002;12(7):R236-8.
56. Zhang-Sun G et al. A 60-kilodalton protein in rat hepatoma cells overexpressing insulin receptor was tyrosine phosphorylated and associated with Syp, phophatidylinositol 3-kinase, and Grb2 in an insulin-dependent manner. Endocrinology. 1996;137(7):2649-58.
57. Moodie SA, Alleman-Sposeto J, Gustafson TA. Identification of the APS protein as a novel insulin receptor substrate. J Biol Chem. 1999;274(16):11186- 93.
58. Pronk GJ et al. Insulin-induced phosphorylation of the 46- and 52-kDa Shc proteins. J Biol Chem. 1993;268(8):5748-53. (Pubitemid 23090902)
59. Huang C et al. Differential contribution of insulin receptor substrates 1 versus 2 to insulin signaling and glucose uptake in l6 myotubes. J Biol Chem. 2005;280(19):19426-35. (Pubitemid 41379651)
60. Previs SF et al. Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. J Biol Chem. 2000;275(50):38990-4. (Pubitemid 32058910)
61. Kido Y et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest. 2000;105(2):199-205. (Pubitemid 30054359)
62. Rhodes CJ, White MF. Molecular insights into insulin action and secretion. Eur J Clin Invest. 2002;32 Suppl 3:3-13. (Pubitemid 41704995)
63. Sadagurski M et al. Insulin receptor substrate 2 plays diverse cell-specific roles in the regulation of glucose transport. J Biol Chem. 2005;280(15):14536-44. (Pubitemid 40562796)
64. Withers DJ et al. Disruption of IRS-2 causes type 2 diabetes inmice. Nature. 1998;391(6670):900-4. (Pubitemid 28157668)
65. Yamauchi T et al. Insulin signalling and insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient mice. Mol Cell Biol. 1996;16(6):3074-84.
66. Tamemoto H et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature. 1994;372(6502):182-6. (Pubitemid 24347838)
67. Araki E et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature. 1994;372(6502):186-90. (Pubitemid 24347839)
68. Kubota N et al. Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. Cell Metab. 2008;8(1):49-64. (Pubitemid 351859226)
69. Tsuruzoe K et al. Insulin receptor substrate 3 (IRS-3) and IRS-4 impair IRS-1- and IRS-2-mediated signaling. Mol Cell Biol. 2001;21(1):26-38.
70. White MF. The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem. 1998;182(1-2):3-11. (Pubitemid 28181643)
71. Backer JM et al. Insulin stimulation of phosphatidylinositol 3-kinase activity maps to insulin receptor regions required for endogenous substrate phosphorylation. J Biol Chem. 1992;267(2):1367-74.
72. Lietzke SE et al. Structural basis of 3-phosphoinositide recognition by pleckstrin homology domains. Mol Cell. 2000;6(2):385-94.
73. Peterson RT, Schreiber SL. Kinase phosphorylation: keeping it all in the family. Curr Biol. 1999;9(14):R521-4. (Pubitemid 29350845)
74. Mackay DJ, Hall A. Rho GTPases. J Biol Chem. 1998;273(33):20685-8. (Pubitemid 28385341)
75. Ziegler SF et al. Molecular cloning and characterization of a novel receptor protein tyrosine kinase from human placenta. Oncogene. 1993;8(3):663-70. (Pubitemid 23093129)
76. Alessi DR et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997;7(4):261-9. (Pubitemid 27176852)
77. Stephens L et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science. 1998;279(5351):710-4. (Pubitemid 28144551)
78. Sarbassov DD et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307(5712):1098-101. (Pubitemid 40262113)
79. Paz K et al. Phosphorylation of insulin receptor substrate-1 (IRS-1) by protein kinase B positively regulates IRS-1 function. J Biol Chem. 1999;274(40):28816-22.
80. Standaert ML et al. Protein kinase C-zeta as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes. Potential role in glucose transport. J Biol Chem. 1997;272(48):30075-82. (Pubitemid 27512203)
81. Chou MM et al. Regulation of protein kinase C zeta by PI 3-kinase and PDK-1. Curr Biol. 1998;8(19):1069-77. (Pubitemid 28451031)
82. Scott PH et al. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci U S A. 1998;95(13):7772-7. (Pubitemid 28293329)
83. Cross DA et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378(6559):785-9. (Pubitemid 26004411)
84. LiXet al. Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator. Nature. 2007;447(7147):1012-6.
85. Nakae J, Park BC, Accili D. Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J Biol Chem. 1999;274(23):15982-5.
86. Cook SA et al. Transcriptional effects of chronic Akt activation in the heart. J Biol Chem. 2002;277(25):22528-33. (Pubitemid 34967227)
87. Yoon JC et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature. 2001;413(6852):131-8. (Pubitemid 32867868)
88. Puigserver P et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature. 2003;423(6939):550-5. (Pubitemid 36648580)
89. Boulton TG et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell. 1991;65(4):663-75.
90. Lazar DF et al. Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. J Biol Chem. 1995;270(35):20801-7.
91. Noguchi T et al. Role of SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in insulin-stimulated Ras activation. Mol Cell Biol. 1994;14(10):6674-82. (Pubitemid 24299736)
92. Sasaoka T et al. Evidence for a functional role of Shc proteins in mitogenic signaling induced by insulin, insulin-like growth factor-1, and epidermal growth factor. J Biol Chem. 1994;269(18):13689-94. (Pubitemid 24206151)
93. Moscat J, Diaz-Meco MT. Feedback on fat: p62-mTORC1-autophagy connections. Cell. 2011;147(4):724-7.
94. Raught B, Gingras AC, Sonenberg N. The target of rapamycin (TOR) proteins. Proc Natl Acad Sci U S A. 2001;98(13):7037-44. (Pubitemid 32567899)
95. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471-84. (Pubitemid 43199434)
96. Peterson TR et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 2009;137(5):873-86.
97. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell. 2009;136(4):731-45.
98. Alessi DR, Pearce LR, Garcia-Martinez JM. New insights into mTOR signaling: mTORC2 and beyond. Sci Signal. 2009;2(67):pe27.
99. Laplante M, Sabatini DM. An emerging role of mTOR in lipid biosynthesis. Curr Biol. 2009;19(22):R1046-52.
100. Avruch J et al. Amino acid regulation of TOR complex 1. Am J Physiol Endocrinol Metab. 2009;296(4):E592-602.
101. Manning BD, Cantley LC. Rheb fills a GAP between TSC and TOR. Trends Biochem Sci. 2003;28(11):573-6. (Pubitemid 38352801)
102. Nave BT et al. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J. 1999;344(Pt 2):427-31. (Pubitemid 30011599)
103. Tzatsos A, Kandror KV. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol. 2006;26(1):63-76.
104. Tremblay F, Marette A. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem. 2001;276(41):38052-60.
105. Tremblay F et al. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology. 2005;146(3):1328-37. (Pubitemid 40289320)
106. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106(2):171-6. (Pubitemid 30483118)
107. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med. 1999;245(6):621-5. (Pubitemid 29278870)
108. Ogg S, Ruvkun G. The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. Mol Cell. 1998;2(6):887-93. (Pubitemid 128378996)
109. Wada T et al. Role of the Src homology 2 (SH2) domain and C-terminus tyrosine phosphorylation sites of SH2-containing inositol phosphatase (SHIP) in the regulation of insulin-induced mitogenesis. Endocrinology. 1999;140(10):4585-94. (Pubitemid 30666124)
110. Lazar DF, Saltiel AR. Lipid phosphatases as drug discovery targets for type 2 diabetes. Nat Rev Drug Discov. 2006;5(4):333-42.
111. Sigal YJ, McDermott MI, Morris AJ. Integral membrane lipid phosphatases/phosphotransferases: common structure and diverse functions. Biochem J. 2005;387(Pt 2):281-93. (Pubitemid 40575751)
112. Mistafa O et al. Purinergic receptor-mediated rapid depletion of nuclear phosphorylated Akt depends on pleckstrin homology domain leucine-rich repeat phosphatase, calcineurin, protein phosphatase 2A, and PTEN phosphatases. J Biol Chem. 2010;285(36):27900-10.
113. Finck BN et al. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. Cell Metab. 2006;4(3):199-210. (Pubitemid 44283957)
114. Peterson TR et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell. 2011;146(3):408-20.
115. Armstrong CG, Doherty MJ, Cohen PT. Identification of the separate domains in the hepatic glycogen-targeting subunit of protein phosphatase 1 that interact with phosphorylase a, glycogen and protein phosphatase 1. Biochem J. 1998;336(Pt 3):699-704. (Pubitemid 29008030)
116. Wong RH, Sul HS. Insulin signaling in fatty acid and fat synthesis: a transcriptional perspective. Curr Opin Pharmacol. 2010;10(6):684-91.
117. Galbo T et al. Free fatty acid-induced PP2A hyperactivity selectively impairs hepatic insulin action on glucose metabolism. PLoS One. 2011;6(11):e27424.
118. Yan L, et al. The B55 α-containing PP2A holoenzyme dephosphorylates FOXO1 in islet β-cells under oxidative stress. Biochem J. 2012;444(2):239-47.
119. Andreozzi F et al. Increased levels of the Akt-specific phosphatase PH domain leucine-rich repeat protein phosphatase (PHLPP)-1 in obese participants are associated with insulin resistance. Diabetologia. 2011;54(7):1879-87.
120. Xiao L et al. Protein phosphatase-1 regulates Akt1 signal transduction pathway to control gene expression, cell survival and differentiation. Cell Death Differ. 2010;17(9):1448-62.
121. Andjelkovic M et al. Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc Natl Acad Sci U S A. 1996;93(12):5699-704. (Pubitemid 26190743)
122. Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell. 2005;18(1):13-24. (Pubitemid 40444644)
123. Brautigan DL, Bornstein P, Gallis B. Phosphotyrosyl-protein phosphatase. Specific inhibition by Zn. J Biol Chem. 1981;256(13):6519-22.
124. Schaapveld R, Wieringa B, Hendriks W. Receptor-like protein tyrosine phosphatases: alike and yet so different. Mol Biol Rep. 1997;24(4):247-62. (Pubitemid 27506833)
125. Alonso A et al. Protein tyrosine phosphatases in the human genome. Cell. 2004;117(6):699-711. (Pubitemid 38748887)
126. Koren S, Fantus IG. Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus. Best Pract Res Clin Endocrinol Metab. 2007;21(4):621-40. (Pubitemid 350185860)
127. Hashimoto N et al. Insulin receptor protein-tyrosine phosphatases. Leukocyte common antigen-related phosphatase rapidly deactivates the insulin receptor kinase by preferential dephosphorylation of the receptor regulatory domain. J Biol Chem. 1992;267(20):13811-4.
128. Frangioni JV et al. The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence. Cell. 1992;68(3):545-60.
129. Egawa K et al. Protein-tyrosine phosphatase-1B negatively regulates insulin signaling in l6 myocytes and Fao hepatoma cells. J Biol Chem. 2001;276(13):10207-11.
130. Goldstein BJ et al. Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein. J Biol Chem. 2000;275(6):4283-9. (Pubitemid 30094668)
131. Dubois MJ et al. The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat Med. 2006;12(5):549-56.
132. Kuhne MR et al. Dephosphorylation of insulin receptor substrate 1 by the tyrosine phosphatase PTP2C. J Biol Chem. 1994;269(22):15833-7. (Pubitemid 24202182)
133. Kulas DTet al. Insulin receptor signaling is augmented by antisense inhibition of the protein tyrosine phosphatase LAR. J Biol Chem. 1995;270(6):2435-8.
134. Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia. 1978;14(3):141-8. (Pubitemid 8286141)
135. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-7. (Pubitemid 46024993)
136. Plum L, Belgardt BF, Bruning JC. Central insulin action in energy and glucose homeostasis. J Clin Invest. 2006;116(7):1761-6. (Pubitemid 44033295)
137. Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489(7415):242-9.
138. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010;140(6):900-17.
139. Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(2):92-103.
140. Patel N, Huang C, Klip A. Cellular location of insulin-triggered signals and implications for glucose uptake. Pflugers Arch. 2006;451(4):499-510. (Pubitemid 41789790)
141. Filippi BM et al. Insulin activates Erk1/2 signaling in the dorsal vagal complex to inhibit glucose production. Cell Metab. 2012;16(4):500-10.
142. Ozcan L et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 2009;9(1):35-51.
143. Ahmad F, Goldstein BJ. Functional association between the insulin receptor and the transmembrane protein-tyrosine phosphatase LAR in intact cells. J Biol Chem. 1997;272(1):448-57. (Pubitemid 27021179)
144. Norris K et al. Expression of protein-tyrosine phosphatases in the major insulin target tissues. FEBS Lett. 1997;415(3):243-8. (Pubitemid 27451941)
145. Zhang WR et al. Modulation of insulin signal transduction by eutopic overexpression of the receptor-type protein-tyrosine phosphatase LAR. Mol Endocrinol. 1996;10(5):575-84.
146. Li PM, Zhang WR, Goldstein BJ. Suppression of insulin receptor activation by overexpression of the protein-tyrosine phosphatase LAR in hepatoma cells. Cell Signal. 1996;8(7):467-73. (Pubitemid 27028857)
147. Ren JMet al. Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis. Diabetes. 1998;47(3):493-7.
148. Zabolotny JM et al. Overexpression of the LAR (leukocyte antigen-related) protein-tyrosine phosphatase in muscle causes insulin resistance. Proc Natl Acad Sci U S A. 2001;98(9): 5187-92. (Pubitemid 32397104)
149. Ahmad F, Considine RV, Goldstein BJ. Increased abundance of the receptor-type protein-tyrosine phosphatase LAR accounts for the elevated insulin receptor dephosphorylating activity in adipose tissue of obese human subjects. J Clin Invest. 1995;95(6):2806-12.
150. Ahmad F, Goldstein BJ. Increased abundance of specific skeletal muscle protein-tyrosine phosphatases in a genetic model of insulin-resistant obesity and diabetes mellitus. Metabolism. 1995;44(9):1175-84. (Pubitemid 26084039)
151. Um JW, Ko J. LAR-RPTPs: synaptic adhesion molecules that shape synapse development. Trends Cell Biol. 2013;23(10):465-75.
152. Garcia-San Frutos M et al. Involvement of protein tyrosine phosphatases and inflammation in hypothalamic insulin resistance associated with ageing: effect of caloric restriction. Mech Ageing Dev. 2012;133(7):489-97.
153. Elchebly M et al. Neuroendocrine dysplasia in mice lacking protein tyrosine phosphatase sigma. Nat Genet. 1999;21(3):330-3. (Pubitemid 29124946)
154. Wallace MJ et al. Neuronal defects and posterior pituitary hypoplasia in mice lacking the receptor tyrosine phosphatase PTPsigma. Nat Genet. 1999;21(3):334-8. (Pubitemid 29124947)
155. Lam CK, Chari M, Lam TK. CNS regulation of glucose homeostasis. Physiology (Bethesda). 2009;24:159-70.
156. Hendriks WJ, Pulido R. Protein tyrosine phosphatase variants in human hereditary disorders and disease susceptibilities. Biochim Biophys Acta. 2013;1832(10):1673-96.
157. Tagami S et al. Troglitazone ameliorates abnormal activity of protein tyrosine phosphatase in adipose tissues of Otsuka Long-Evans Tokushima Fatty rats. Tohoku J Exp Med. 2002;197(3):169-81. (Pubitemid 35378740)
158. Gonzalez-Rodriguez A et al. Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging. Aging Cell. 2012;11(2):284-96.
159. Zabolotny JM et al. Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo. J Biol Chem. 2008;283(21):14230-41.
160. Elchebly M et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 1999;283(5407):1544-8.
161. Delibegovic M et al. Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes. 2009;58(3):590-9.
162. Agouni A, et al. Liver-specific deletion of protein tyrosine phosphatase (PTP) 1B improves obesity- and pharmacologically induced endoplasmic reticulum stress. Biochem J. 2011;438(2):369-78.
163. Owen C et al. Inducible liver-specific knockdown of protein tyrosine phosphatase 1B improves glucose and lipid homeostasis in adult mice. Diabetologia. 2013;56(10):2286-96.
164. Bakke J et al. Regulation of the SNARE-interacting protein Munc18c tyrosine phosphorylation in adipocytes by protein-tyrosine phosphatase 1B. Cell Commun Signal. 2013;11(1):57.
165. Song DD et al. Protein tyrosine phosphatase 1B inhibits adipocyte differentiation and mediates TNFalpha action in obesity. Biochim Biophys Acta. 2013;1831(8):1368-76.
166. Owen C et al. Adipocyte-specific protein tyrosine phosphatase 1B deletion increases lipogenesis, adipocyte cell size and is a minor regulator of glucose homeostasis. PLoS One. 2012;7(2):e32700.
167. Delibegovic M et al. Improved glucose homeostasis in mice with muscle-specific deletion of protein-tyrosine phosphatase 1B. Mol Cell Biol. 2007;27(21):7727-34. (Pubitemid 350033677)
168. Picardi PK et al. Modulation of hypothalamic PTP1B in the TNF-alpha-induced insulin and leptin resistance. FEBS Lett. 2010;584(14):3179- 84.
169. Zhang J et al. Protein tyrosine phosphatase 1B deficiency ameliorates murine experimental colitis via the expansion of myeloid-derived suppressor cells. PLoS One. 2013;8(8):e70828.
170. Nasimian A et al. Protein tyrosine phosphatase 1B (PTP1B) modulates palmitate-induced cytokine production in macrophage cells. Inflamm Res. 2013;62(2):239-46.
171. Xu H et al. Phosphatase PTP1B negatively regulates MyD88- and TRIF-dependent proinflammatory cytokine and type I interferon production in TLR-triggered macrophages. Mol Immunol. 2008;45(13):3545-52.
172. Pandey NR et al. The LIM domain only 4 protein is a metabolic responsive inhibitor of protein tyrosine phosphatase 1B that controls hypothalamic leptin signaling. J Neurosci. 2013;33(31):12647-55.
173. Bettaieb A et al. Differential regulation of endoplasmic reticulum stress by protein tyrosine phosphatase 1B and Tcell protein tyrosine phosphatase. J Biol Chem. 2011;286(11):9225-35.
174. White CL et al. HF diets increase hypothalamic PTP1B and induce leptin resistance through both leptin-dependent and -independent mechanisms. Am J Physiol Endocrinol Metab. 2009;296(2):E291-9.
175. Bence KK et al. Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med. 2006;12(8):917-24. (Pubitemid 44175143)
176. Banno R et al. PTP1B and SHP2 in POMC neurons reciprocally regulate energy balance inmice. J Clin Invest. 2010;120(3):720-34.
177. Gu F et al. Protein-tyrosine phosphatase 1B potentiates IRE1 signaling during endoplasmic reticulum stress. J Biol Chem. 2004;279(48):49689-93. (Pubitemid 39577772)
178. Snider NT, Park H, Omary MB. A conserved rod domain phosphotyrosine that is targeted by the phosphatase PTP1B promotes keratin 8 insolubility and filament organization. J Biol Chem. 2013;288(43):31329-37.
179. Chiarugi P et al. LMW-PTP is a negative regulator of insulin-mediated mitotic and metabolic signalling. Biochem Biophys Res Commun. 1997;238(2):676-82. (Pubitemid 27464449)
180. Pandey SK et al. Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice. J Biol Chem. 2007;282(19):14291-9. (Pubitemid 47100476)
181. Cho CYet al. Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling. Cell Metab. 2006;3(5):367-78.
182. Moller NP et al. Selective down-regulation of the insulin receptor signal by protein-tyrosine phosphatases alpha and epsilon. J Biol Chem. 1995;270(39):23126-31.
183. Lammers R, Moller NP, Ullrich A. The transmembrane protein tyrosine phosphatase alpha dephosphorylates the insulin receptor in intact cells. FEBS Lett. 1997;404(1):37-40. (Pubitemid 27107803)
184. Cong LN et al. Overexpression of protein tyrosine phosphatase-alpha (PTP-alpha) but not PTP-kappa inhibits translocation of GLUT4 in rat adipose cells. Biochem Biophys Res Commun. 1999;255(2):200-7.
185. Kapp K et al. The protein tyrosine phosphatase alpha modifies insulin secretion in INS-1E cells. Biochem Biophys Res Commun. 2003;311(2):361-4. (Pubitemid 37340085)
186. Arnott CH et al. Use of an antisense strategy to dissect the signaling role of protein-tyrosine phosphatase alpha. J Biol Chem. 1999;274(37):26105-12.
187. Le HT, Ponniah S, Pallen CJ. Insulin signaling and glucose homeostasis in mice lacking protein tyrosine phosphatase alpha. Biochem Biophys Res Commun. 2004;314(2):321-9. (Pubitemid 38084720)
188. Andersen JN et al. Comparative study of protein tyrosine phosphatase-epsilon isoforms: membrane localization confers specificity in cellular signalling. Biochem J. 2001;354(Pt 3):581-90. (Pubitemid 32269721)
189. Aga-Mizrachi S et al. Cytosolic protein tyrosine phosphatase-epsilon is a negative regulator of insulin signaling in skeletal muscle. Endocrinology. 2008;149(2):605-14. (Pubitemid 351159339)
190. Faisal A et al. Serine/threonine phosphorylation of ShcA. Regulation of protein-tyrosine phosphatase-pest binding and involvement in insulin signaling. J Biol Chem. 2002;277(33):30144-52.
191. Galic S et al. Regulation of insulin receptor signaling by the protein tyrosine phosphatase TCPTP. Mol Cell Biol. 2003;23(6):2096-108. (Pubitemid 36278819)
192. Xu J et al. Effects of small interference RNA against PTP1B and TCPTP on insulin signaling pathway in mouse liver: evidence for non-synergetic cooperation. Cell Biol Int. 2007;31(1):88-91. (Pubitemid 46124032)
193. Fukushima A et al. T-cell protein tyrosine phosphatase attenuates STAT3 and insulin signaling in the liver to regulate gluconeogenesis. Diabetes. 2010;59(8):1906-14.
194. Loh K et al. Tcell protein tyrosine phosphatase (TCPTP) deficiency in muscle does not alter insulin signalling and glucose homeostasis in mice. Diabetologia. 2012;55(2):468-78.
195. Zee T et al. T-cell protein tyrosine phosphatase regulates bone resorption and whole-body insulin sensitivity through its expression in osteoblasts. Mol Cell Biol. 2012;32(6):1080-8.
196. Rajshankar D et al. Role of PTPalpha in the destruction of periodontal connective tissues. PLoS One. 2013;8(8):e70659.
197. Tiganis T. PTP1B and TCPTP- nonredundant phosphatases in insulin signaling and glucose homeostasis. FEBS J. 2013;280(2):445-58.
198. Loh K et al. Elevated hypothalamic TCPTP in obesity contributes to cellular leptin resistance. Cell Metab. 2011;14(5):684-99.
199. Tsui HW et al. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat Genet. 1993;4(2):124-9.
200. Shultz LD et al. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell. 1993;73(7):1445-54. (Pubitemid 23201156)
201. Qu CK. Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response. Biochim Biophys Acta. 2002;1592(3):297-301.
202. Poole AW, Jones ML. A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail. Cell Signal. 2005;17(11):1323-32. (Pubitemid 41206642)
203. Chong ZZ, Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol. 2007;22(11):1251-67. (Pubitemid 47470319)
204. Banville D, Stocco R, Shen SH. Human protein tyrosine phosphatase 1C (PTPN6) gene structure: alternate promoter usage and exon skipping generate multiple transcripts. Genomics. 1995;27(1):165-73.
205. Jin YJ, Yu CL, Burakoff SJ. Human 70-kDa SHP-1L differs from 68-kDa SHP-1 in its C-terminal structure and catalytic activity. J Biol Chem. 1999;274(40):28301-7.
206. Yi TL, Cleveland JL, Ihle JN. Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. Mol Cell Biol. 1992;12(2):836-46.
207. Horvat A et al. A novel role for protein tyrosine phosphatase shp1 in controlling glial activation in the normal and injured nervous system. J Neurosci. 2001;21(3):865-74. (Pubitemid 32163128)
208. Lurie DI et al. Tyrosine phosphatase SHP-1 immunoreactivity increases in a subset of astrocytes following deafferentation of the chicken auditory brainstem. J Comp Neurol. 2000;421(2):199-214. (Pubitemid 30246970)
209. Massa PT et al. Expression and function of the protein tyrosine phosphatase SHP-1 in oligodendrocytes. Glia. 2000;29(4):376-85. (Pubitemid 30121427)
210. Kim HY et al. Raft-mediated Src homology 2 domain-containing proteintyrosine phosphatase 2 (SHP-2) regulation in microglia. J Biol Chem. 2006;281(17):11872-8.
211. Valencia AM et al. Identification of a protein-tyrosine phosphatase (SHP1) different from that associated with acid phosphatase in rat prostate. FEBS Lett. 1997;406(1-2):42-8.
212. Vogel W et al. Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. Science. 1993;259(5101):1611-4. (Pubitemid 23114640)
213. Yang J et al. Crystal structure of human protein-tyrosine phosphatase SHP-1. J Biol Chem. 2003;278(8):6516-20. (Pubitemid 36800913)
214. Plutzky J, Neel BG, Rosenberg RD. Isolation of a src homology 2-containing tyrosine phosphatase. Proc Natl Acad Sci U S A. 1992;89(3):1123-7.
215. Ren L et al. Substrate specificity of protein tyrosine phosphatases 1B, RPTPalpha, SHP-1, and SHP-2. Biochemistry. 2011;50(12):2339-56.
216. Yang J et al. Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1. J Biol Chem. 1998;273(43):28199-207. (Pubitemid 28496118)
217. Liu W, et al. Identification of cryptotanshinone as an inhibitor of Oncogenic protein tyrosine phosphatase SHP2 (PTPN11). J Med Chem. 2013;56(18):7212-21.
218. Pei D et al. Intramolecular regulation of protein tyrosine phosphatase SH-PTP1: a new function for Src homology 2 domains. Biochemistry. 1994;33(51):15483-93.
219. Zhao Z et al. Purification and characterization of a protein tyrosine phosphatase containing SH2 domains. J Biol Chem. 1993;268(4):2816-20. (Pubitemid 23057914)
220. Bennett AM et al. Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc Natl Acad Sci U S A. 1994;91(15):7335-9.
221. Frank C et al. Effective dephosphorylation of Src substrates by SHP-1. J Biol Chem. 2004;279(12):11375-83. (Pubitemid 38401636)
222. Uchida Tet al. Insulin stimulates the phosphorylation of Tyr538 and the catalytic activity of PTP1C, a protein tyrosine phosphatase with Src homology-2 domains. J Biol Chem. 1994;269(16):12220-8.
223. Hsu MF, Meng TC. Enhancement of insulin responsiveness by nitric oxide-mediated inactivation of protein-tyrosine phosphatases. J Biol Chem. 2009;285(11):7919-28.
224. Ozawa T et al. Negative autoregulation of Src homology region 2-domain-containing phosphatase-1 in rat basophilic leukemia-2H3 cells. Int Immunol. 2007;19(9):1049-61. (Pubitemid 47434238)
225. Tenev T et al. Perinuclear localization of the protein-tyrosine phosphatase SHP-1 and inhibition of epidermal growth factor-stimulated STAT1/3 activation in A431 cells. Eur J Cell Biol. 2000;79(4):261-71. (Pubitemid 30232571)
226. Ram PA, Waxman DJ. Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase. J Biol Chem. 1997;272(28):17694-702. (Pubitemid 27311207)
227. Yang W, Tabrizi M, Yi T. A bipartite NLS at the SHP-1 C-terminus mediates cytokine-induced SHP-1 nuclear localization in cell growth control. Blood Cells Mol Dis. 2002;28(1):63-74. (Pubitemid 34408989)
228. Craggs G, Kellie S. A functional nuclear localization sequence in the C-terminal domain of SHP-1. J Biol Chem. 2001;276(26):23719-25.
229. Watanabe N, et al. Heterogeneous nuclear ribonucleoprotein Q (hnRNP Q) is a novel substrate of SH2 domain-containing phosphatase-2 (SHP2). J Biochem. 2013;154(5):475-80.
230. Xu E, et al. Hepatocyte-specific Ptpn6 deletion protects from obesity-linked hepatic insulin resistance. Diabetes. 2012;61(8):1949-58.
231. Yu Z et al. SHP-1 associateswith both platelet-derived growth factor receptor and the p85 subunit of phosphatidylinositol 3-kinase. J Biol Chem. 1998;273(6):3687-94. (Pubitemid 28109796)
232. Cuevas BD et al. Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J Biol Chem. 2001;276(29):27455-61.
233. Lu Yet al. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem. 2003;278(41):40057-66.
234. Cui TX et al. Angiotensin II subtype 2 receptor activation inhibits insulin-induced phosphoinositide 3-kinase and Akt and induces apoptosis in PC12W cells. Mol Endocrinol. 2002;16(9):2113-23.
235. Bergeron S et al. Inhibition of the protein tyrosine phosphatase SHP-1 increases glucose uptake in skeletal muscle cells by augmenting insulin receptor signaling and GLUT4 expression. Endocrinology. 2011;152(12):4581-8.
236. Oriente F et al. Prep1 controls insulin glucoregulatory function in liver by transcriptional targeting of SHP1 tyrosine phosphatase. Diabetes. 2011;60(1):138-47.
237. Fiset A et al. Compartmentalized CDK2 is connected with SHP-1 and beta-catenin and regulates insulin internalization. Cell Signal. 2011;23(5):911-9.
238. Kahn CR et al. Quantitative aspects of the insulin-receptor interaction in liver plasma membranes. J Biol Chem. 1974;249(7):2249-57.
239. Jaspan JB et al. Hepatic metabolism of glucagon in the dog: contribution of the liver to overall metabolic disposal of glucagon. Am J Physiol. 1981;240(3):E233-44. (Pubitemid 11137934)
240. Sato H et al. Receptor-recycling model of clearance and distribution of insulin in the perfused mouse liver. Diabetologia. 1991;34(9):613-21.
241. Burgess JW et al. Pharmacological doses of insulin equalize insulin receptor phosphotyrosine content but not tyrosine kinase activity in plasmalemmal and endosomal membranes. Biochem Cell Biol. 1992;70(10-11):1151-8.
242. Bergeron JJ et al. Uptake of insulin and other ligands into receptor-rich endocytic components of target cells: the endosomal apparatus. Annu Rev Physiol. 1985;47:383-403. (Pubitemid 15142388)
243. Yoshii H et al. Effects of portal free fatty acid elevation on insulin clearance and hepatic glucose flux. Am J Physiol Endocrinol Metab. 2006;290(6):E1089-97. (Pubitemid 43847891)
244. Kotronen A et al. Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab. 2007;293(6):E1709-15. (Pubitemid 350255123)
245. Doherty 2nd JJ et al. Selective degradation of insulin within rat liver endosomes. J Cell Biol. 1990;110(1):35-42.
246. Backer JM, Kahn CR, White MF. The dissociation and degradation of internalized insulin occur in the endosomes of rat hepatoma cells. J Biol Chem. 1990;265(25):14828-35.
247. Di Guglielmo GM et al. Insulin receptor internalization and signalling. Mol Cell Biochem. 1998;182(1-2):59-63. (Pubitemid 28181648)
248. Valera Mora ME et al. Insulin clearance in obesity. J Am Coll Nutr. 2003;22(6):487-93. (Pubitemid 38010014)
249. Xu E et al. Targeted disruption of carcinoembryonic antigen-related cell adhesion molecule 1 promotes diet-induced hepatic steatosis and insulin resistance. Endocrinology. 2009;150(8):3503-12.
250. Najjar SM. Regulation of insulin action by CEACAM1. Trends Endocrinol Metab. 2002;13(6):240-5. (Pubitemid 36733968)
251. Huber M, Izzi L, Grondin P, Houde C, Kunath T, Veillette A, et al. The carboxyl-terminal region of biliary glycoprotein controls its tyrosine phosphorylation and association with protein-tyrosine phosphatases SHP-1 and SHP-2 in epithelial cells. J Biol Chem. 1999;274(1):335-44. (Pubitemid 29035067)
252. Rocchi S et al. Interaction of SH2-containing protein tyrosine phosphatase 2 with the insulin receptor and the insulin-like growth factor-I receptor: studies of the domains involved using the yeast two-hybrid system. Endocrinology. 1996;137(11):4944-52. (Pubitemid 26403338)
253. Walchli S et al. Identification of tyrosine phosphatases that dephosphorylate the insulin receptor. A brute force approach based on "substrate-trapping" mutants. J Biol Chem. 2000;275(13):9792-6. (Pubitemid 30185214)
254. Maegawa H et al. SHPTP2 serves adapter protein linking between Janus kinase 2 and insulin receptor substrates. Biochem Biophys Res Commun. 1996;228(1):122-7. (Pubitemid 26390640)
255. Arrandale JM et al. Insulin signaling in mice expressing reduced levels of Syp. J Biol Chem. 1996;271(35):21353-8. (Pubitemid 26292997)
256. Maegawa H et al. Expression of a dominant negative SHP-2 in transgenic mice induces insulin resistance. J Biol Chem. 1999;274(42):30236-43.
257. Fukunaga K et al. Requirement for protein-tyrosine phosphatase SHP-2 in insulin-induced activation of c-Jun NH(2)-terminal kinase. J Biol Chem. 2000;275(7):5208-13. (Pubitemid 30108925)
258. Tanaka S et al. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology. 1997;26(3):598-604. (Pubitemid 27392349)
259. Hayashi K et al. Insulin receptor substrate-1/SHP-2 interaction, a phenotype-dependent switching machinery of insulin-like growth factor-I signaling in vascular smooth muscle cells. J Biol Chem. 2004;279(39):40807-18. (Pubitemid 39287678)
260. Mussig K et al. Shp2 is required for protein kinase C-dependent phosphorylation of serine 307 in insulin receptor substrate-1. J Biol Chem. 2005;280(38):32693-9. (Pubitemid 41368314)
261. Princen F et al. Deletion of Shp2 tyrosine phosphatase in muscle leads to dilated cardiomyopathy, insulin resistance, and premature death. Mol Cell Biol. 2009;29(2):378-88.
262. Matsuo K et al. Altered glucose homeostasis in mice with liver-specific deletion of Src homology phosphatase 2. J Biol Chem. 2010;285(51):39750-8.
263. Nagata N et al. Hepatic Src homology phosphatase 2 regulates energy balance in mice. Endocrinology. 2012;153(7):3158-69.
264. Bettaieb A et al. Adipose-specific deletion of Src homology phosphatase 2 does not significantly alter systemic glucose homeostasis. Metabolism. 2011;60(8):1193-201.
265. He Z et al. Nonreceptor tyrosine phosphatase Shp2 promotes adipogenesis through inhibition of p38 MAP kinase. Proc Natl Acad Sci U S A. 2013;110(1):E79-88.
266. Yu J et al. Modulation of fatty acid synthase degradation by concerted action of p38 MAP kinase, E3 ligase COP1, and SH2-tyrosine phosphatase Shp2. J Biol Chem. 2013;288(6):3823-30.
267. Levy DE, Darnell Jr JE. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3(9):651-62. (Pubitemid 34987786)
268. Reich NC, Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol. 2006;6(8):602-12. (Pubitemid 44134093)
269. Xu D, Qu CK. Protein tyrosine phosphatases in the JAK/STAT pathway. Front Biosci. 2008;13:4925-32. (Pubitemid 351599646)
270. Tsou RC, Bence KK. Central regulation of metabolism by protein tyrosine phosphatases. Front Neurosci. 2012;6:192.
271. Takahashi A et al. SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver. Mol Cell. 2011;43(1):45-56.
272. Duchesne C et al. Negative regulation of beta-catenin signaling by tyrosine phosphatase SHP-1 in intestinal epithelial cells. J Biol Chem. 2003;278(16):14274-83. (Pubitemid 36799976)
273. Simoneau M et al. SHP-1 inhibits beta-catenin function by inducing its degradation and interfering with its association with TATA-binding protein. Cell Signal. 2011;23(1):269-79.
274. Liang LF et al. Cembrane diterpenoids from the soft coral Sarcophyton trocheliophorum Marenzeller as a new class of PTP1B inhibitors. Bioorg Med Chem. 2013;21(17):5076-80.
275. Zhang W et al. Ursolic acid and its derivative inhibit protein tyrosine phosphatase 1B, enhancing insulin receptor phosphorylation and stimulating glucose uptake. Biochim Biophys Acta. 2006;1760(10):1505-12. (Pubitemid 44428024)
276. Hsu MF, Meng TC. Enhancement of insulin responsiveness by nitric oxide-mediated inactivation of protein-tyrosine phosphatases. J Biol Chem. 2010;285(11):7919-28.
277. Zhang S et al. A highly selective and potent PTP-MEG2 inhibitor with therapeutic potential for type 2 diabetes. J Am Chem Soc. 2012;134(43):18116-24.
278. Lorenzen JA, Dadabay CY, Fischer EH. COOH-terminal sequence motifs target the T cell protein tyrosine phosphatase to the ER and nucleus. J Cell Biol. 1995;131(3):631-43.
279. Chughtai N et al. Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the beta-casein gene promoter in mammary cells. J Biol Chem. 2002;277(34):31107-14. (Pubitemid 34970816)
280. Wu TR et al. SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei. J Biol Chem. 2002;277(49):47572-80. (Pubitemid 36159277)
281. Wang Y et al. Proteomic analysis reveals novel molecules involved in insulin signaling pathway. J Proteome Res. 2006;5(4):846-55.
282. Kruger M et al. Dissection of the insulin signaling pathway via quantitative phosphoproteomics. Proc Natl Acad Sci U S A. 2008;105(7):2451-6. (Pubitemid 351520534)
283. Hornbeck PV et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res. 2012;40(Database issue): D261-70.